Close

Applied DNA Sciences (APDN) Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

Go back to Applied DNA Sciences (APDN) Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

Applied DNA Provides Update on Linear-DNA COVID-19 Vaccine Candidates Development Program

June 8, 2020 8:26 AM EDT

- Anticipates Linear DNA Dose-Response Preclinical Trial Results in June -

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences Inc. (NASDAQ: APDN) (Applied DNA or the Company) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and anti-theft technology, today provided an update related to the development of linear-DNA form of COVID-19 vaccine candidates with development partner Takis Biotech (Takis). Subsequent to the Companys announcement on... More